- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
BCRF investigators report DNA modifications in breast cancer risk genes may be a result of combined genetic and environmental causes.
BCRF investigators join forces to launch BFOR, an innovative study offering genetic testing for women and men of Ashkenazi Jewish ancestry.
A computer modeling system developed by BCRF investigators allows scientists to simulate tumor cell behavior.
Valentine’s Day is a celebration of love and intimacy, but a breast cancer diagnosis can get in the way.
BCRF investigators report that women at a healthy weight but with high levels of body fat may have an increased risk of breast cancer after menopause.
A study led by BCRF investigator Fergus Couch has shown that 54 BRCA2 variants of uncertain clinical significance are likely to be associated with an increased risk of breast or ovarian cancer.
In Part Three of our series, we explain how to adopt a balanced lifestyle to achieve your wellness goals.
BCRF researchers have uncovered new information about inherited risk of breast cancer for women of Ashkenazi (European) Jewish ancestry. The report was recently published in JAMA Oncology.
FDA approves the first PARP inhibitor for the treatment of HER2-negative metastatic breast cancer in patients with BRCA mutations.
Blood Test Provides Important Prognostic Information for Metastatic Triple Negative Breast Cancer Patients
Research by BCRF investigators shows that tumor DNA collected by liquid biopsy can identify patients at risk of poor outcome.